Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CBL-514 for Reducing Abdominal Subcutaneous Fat
NCT05736107Phase 2Completed
- Sponsor
- Caliway Biopharmaceuticals
- Start
- May 2023
- Primary completion
- May 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial comparing CBL-514 Injection with Placebo (2 arms). Primary endpoint: Proportion of participants with at least 1-grade improvement on Clinician-Reported Abdominal Fat Rating Scale. Started May 2023; status: completed.
02
Drugs
CBL-514
Beyond the preview
Go deeper on NCT05736107.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05736107.